Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 417

Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Loncastuximab and Roflumilast in Combination with R-CHOP (Lo-RR-CHOP) for the Treatment of High-Risk Diffuse Large B-cell Lymphoma
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Ruxolitinib in Combination with CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Calaspargase Pegol plus Combination Chemotherapy for the Treatment of Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Genetically Engineered Cells (8R-70CAR T Cells) in Combination with Standard Temozolomide and Radiation Therapy with or without Conditioning Chemotherapy for Treatment of CD70 Positive Adult Glioblastoma and Pediatric High Grade Gliomas, IMPACT Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Total Body Irradiation Using Intensity Modulated Radiation Therapy and Cyclophosphamide prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Status: Active
Location: 2 locations
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: Active
Location: See ClinicalTrials.gov
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Status: Active
Location: See ClinicalTrials.gov
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
Autologous CAR19.20.22 Chimeric Antigen Receptor T Cells (CAR19.20.22 CART) for the Treatment of Recurrent or Refractory B-Cell Lymphomas
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Status: Enrolling by Invitation
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Combination Study of SV-BR-1-GM With Retifanlimab
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
CD70.CAR NK Cells for the Treatment of Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
Evaluation of JV-394 Autologous Anti-CD94 Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory CD94+ T/NK-cell neoplasms
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Modified T Cells (UF-KURE-BCMA CAR-T Cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations